Cagrilintide 10mg

Cagrilintide is a long-acting acylated analogue of human amylin (islet amyloid polypeptide, IAPP), developed by Novo Nordisk. Amylin is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to nutrient ingestion. Native amylin promotes satiety, slows gastric emptying, and suppresses postprandial glucagon release, but its extremely short half-life (~13 minutes) and tendency to aggregate limit its direct therapeutic application. Cagrilintide incorporates amino acid modifications and a fatty acid side chain (acylation) that enable albumin binding, extending the half-life to approximately 7 days and allowing once-weekly dosing. It activates the calcitonin receptor/receptor activity-modifying protein (RAMP) complex system, particularly CT receptor + RAMP1/2/3 heterodimers, in the area postrema and nucleus of the solitary tract — brainstem regions that integrate satiety signals. Phase II clinical trial results showed cagrilintide produced significant dose-dependent weight loss in adults with overweight or obesity. At the highest dose (4.5 mg weekly), participants lost approximately 10.8% of body weight over 26 weeks, compared to 3.0% with placebo. Cagrilintide is being developed both as a standalone agent and in combination with semaglutide (the CagriSema program).

Cagrilintide is a long-acting acylated analogue of human amylin (islet amyloid polypeptide, IAPP), developed by Novo Nordisk. Amylin is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to nutrient ingestion. Native amylin promotes satiety, slows gastric emptying, and suppresses postprandial glucagon release, but its extremely short half-life (~13 minutes) and tendency to aggregate limit its direct therapeutic application. Cagrilintide incorporates amino acid modifications and a fatty acid side chain (acylation) that enable albumin binding, extending the half-life to approximately 7 days and allowing once-weekly dosing. It activates the calcitonin receptor/receptor activity-modifying protein (RAMP) complex system, particularly CT receptor + RAMP1/2/3 heterodimers, in the area postrema and nucleus of the solitary tract — brainstem regions that integrate satiety signals. Phase II clinical trial results showed cagrilintide produced significant dose-dependent weight loss in adults with overweight or obesity. At the highest dose (4.5 mg weekly), participants lost approximately 10.8% of body weight over 26 weeks, compared to 3.0% with placebo. Cagrilintide is being developed both as a standalone agent and in combination with semaglutide (the CagriSema program).

Phase II trials studied 0.3-4.5 mg subcutaneously once weekly with dose escalation. The CagriSema program combines 2.4 mg cagrilintide + 2.4 mg semaglutide weekly.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.